Susceptibility Testing of Medically Important Parasites

SUMMARY In the last 2 decades, renewed attention to neglected tropical diseases (NTDs) has spurred the development of antiparasitic agents, especially in light of emerging drug resistance. The need for new drugs has required in vitro screening methods using parasite culture. Furthermore, clinical laboratories sought to correlate in vitro susceptibility methods with treatment outcomes, most notably with malaria. Parasites with their various life cycles present greater complexity than bacteria, for which standardized susceptibility methods exist. This review catalogs the state-of-the-art methodologies used to evaluate the effects of drugs on key human parasites from the point of view of drug discovery as well as the need for laboratory methods that correlate with clinical outcomes.

[1]  J. Cotton,et al.  Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Irshad Ahmad,et al.  Copper(II) oxide nanoparticles augment antifilarial activity of Albendazole: In vitro synergistic apoptotic impact against filarial parasite Setaria cervi. , 2016, International journal of pharmaceutics.

[3]  M. Hickman,et al.  Assessment of the Worldwide Antimalarial Resistance Network Standardized Procedure for In Vitro Malaria Drug Sensitivity Testing Using SYBR Green Assay for Field Samples with Various Initial Parasitemia Levels , 2016, Antimicrobial Agents and Chemotherapy.

[4]  R. Richards-Kortum,et al.  Multiplexed Recombinase Polymerase Amplification Assay To Detect Intestinal Protozoa. , 2016, Analytical chemistry.

[5]  Weam I Zaky,et al.  The Effect of In Vitro Cultivation on the Transcriptome of Adult Brugia malayi , 2016, PLoS neglected tropical diseases.

[6]  J. Keiser,et al.  Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays , 2015, Parasites & Vectors.

[7]  E. Chatelain,et al.  Reply to “Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs” , 2015, Antimicrobial Agents and Chemotherapy.

[8]  J. McKerrow,et al.  Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs , 2015, Antimicrobial Agents and Chemotherapy.

[9]  G. Zhu,et al.  Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro , 2015, Front. Microbiol..

[10]  S. Bennuru,et al.  Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal. , 2015, The Journal of infectious diseases.

[11]  Mark A. Miller,et al.  Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). , 2015, The Lancet. Global health.

[12]  L. Cui,et al.  Artemisinin Resistance at the China-Myanmar Border and Association with Mutations in the K13 Propeller Gene , 2015, Antimicrobial Agents and Chemotherapy.

[13]  J. Irelan,et al.  Viability of developmental stages of Schistosoma mansoni quantified with xCELLigence worm real-time motility assay (xWORM) , 2015, International journal for parasitology. Drugs and drug resistance.

[14]  T. Geary,et al.  In vitro flubendazole-induced damage to vital tissues in adult females of the filarial nematode Brugia malayi , 2015, International journal for parasitology. Drugs and drug resistance.

[15]  M. Cipriano,et al.  Genetic modification of the diarrheal pathogen Cryptosporidium parvum , 2015, Nature.

[16]  S. Montgomery,et al.  Something old, something new: is praziquantel enough for schistosomiasis control? , 2015, Future medicinal chemistry.

[17]  C. Cunningham,et al.  What is the mechanism of action of praziquantel and how might resistance strike? , 2015, Future medicinal chemistry.

[18]  Rahul Singh,et al.  The QDREC web server: determining dose-response characteristics of complex macroparasites in phenotypic drug screens , 2015, Bioinform..

[19]  S. Han,et al.  Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  David W. Gray,et al.  A novel multiple-stage antimalarial agent that inhibits protein synthesis , 2015, Nature.

[21]  A. Vaughan,et al.  Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. , 2015, Cell host & microbe.

[22]  Brian M. Suzuki,et al.  Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis , 2015, PLoS neglected tropical diseases.

[23]  S. Altamura,et al.  Development and Validation of a Luminescence-based, Medium-Throughput Assay for Drug Screening in Schistosoma mansoni , 2015, PLoS neglected tropical diseases.

[24]  M. Lewis,et al.  A New Experimental Model for Assessing Drug Efficacy against Trypanosoma cruzi Infection Based on Highly Sensitive In Vivo Imaging , 2015, Journal of biomolecular screening.

[25]  C. Unger,et al.  Lactate as a Novel Quantitative Measure of Viability in Schistosoma mansoni Drug Sensitivity Assays , 2014, Antimicrobial Agents and Chemotherapy.

[26]  K. Kalani,et al.  In Vitro, In Silico and In Vivo Studies of Ursolic Acid as an Anti-Filarial Agent , 2014, PloS one.

[27]  J. B. Dixon,et al.  An Integrated In Vitro Imaging Platform for Characterizing Filarial Parasite Behavior within a Multicellular Microenvironment , 2014, PLoS neglected tropical diseases.

[28]  S. Mukherjee,et al.  In vitro antifilarial activity of Azadirachta indica aqueous extract through reactive oxygen species enhancement. , 2014, Asian Pacific journal of tropical medicine.

[29]  K. Ramaiah,et al.  Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease , 2014, PLoS neglected tropical diseases.

[30]  R. Sinden,et al.  A Male and Female Gametocyte Functional Viability Assay To Identify Biologically Relevant Malaria Transmission-Blocking Drugs , 2014, Antimicrobial Agents and Chemotherapy.

[31]  B. Zhan,et al.  Vaccination with a genetically modified Brugia malayi cysteine protease inhibitor-2 reduces adult parasite numbers and affects the fertility of female worms following a subcutaneous challenge of Mongolian gerbils (Meriones unguiculatus) with B. malayi infective larvae. , 2014, International journal for parasitology.

[32]  Ray Kaplan,et al.  Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: “The Worminator” , 2014, International journal for parasitology. Drugs and drug resistance.

[33]  L. Cui,et al.  Competition between Plasmodium falciparum strains in clinical infections during in vitro culture adaptation. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[34]  X. Vidal,et al.  Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. , 2014, The New England journal of medicine.

[35]  M. Miles,et al.  Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection , 2014, Cellular microbiology.

[36]  M. Bockarie,et al.  Filaria zoogeography in Africa: ecology, competitive exclusion, and public health relevance. , 2014, Trends in parasitology.

[37]  S. Krudsood,et al.  Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.

[38]  G. Ward,et al.  Identification of Cryptosporidium parvum Active Chemical Series by Repurposing the Open Access Malaria Box , 2014, Antimicrobial Agents and Chemotherapy.

[39]  Roger Le Grand,et al.  Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures , 2014, Nature Medicine.

[40]  Ya-jie Li,et al.  An integrated microfludic device for culturing and screening of Giardia lamblia. , 2014, Experimental parasitology.

[41]  D. Horn,et al.  Antiparasitic chemotherapy: from genomes to mechanisms. , 2014, Annual review of pharmacology and toxicology.

[42]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[43]  Saorin Kim,et al.  Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. , 2013, The Lancet. Infectious diseases.

[44]  Ricardo Obonaga,et al.  Treatment Failure and Miltefosine Susceptibility in Dermal Leishmaniasis Caused by Leishmania Subgenus Viannia Species , 2013, Antimicrobial Agents and Chemotherapy.

[45]  Inacio Mandomando,et al.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study , 2013, The Lancet.

[46]  Anne E Carpenter,et al.  A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. , 2013, Cell host & microbe.

[47]  R. Sinden,et al.  Male and Female Plasmodium falciparum Mature Gametocytes Show Different Responses to Antimalarial Drugs , 2013, Antimicrobial Agents and Chemotherapy.

[48]  N. Quashie,et al.  High-Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide Antimalarial Resistance Network (WWARN) In Vitro Analysis and Reporting Tool , 2013, Antimicrobial Agents and Chemotherapy.

[49]  Jeffrey S. Hannam,et al.  A selective inhibitor of heme biosynthesis in endosymbiotic bacteria elicits antifilarial activity in vitro. , 2013, Chemistry & biology.

[50]  L. Tilley,et al.  Altered temporal response of malaria parasites determines differential sensitivity to artemisinin , 2013, Proceedings of the National Academy of Sciences.

[51]  K. Bessoff,et al.  Drug Repurposing Screen Reveals FDA-Approved Inhibitors of Human HMG-CoA Reductase and Isoprenoid Synthesis That Block Cryptosporidium parvum Growth , 2013, Antimicrobial Agents and Chemotherapy.

[52]  S. Sundar,et al.  Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani , 2013, Parasitology Research.

[53]  Catherine Z. Chen,et al.  A Homogenous Luminescence Assay Reveals Novel Inhibitors for Giardia Lamblia Carbamate Kinase , 2012, Current chemical genomics.

[54]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[55]  Saorin Kim,et al.  Reduced Artemisinin Susceptibility of Plasmodium falciparum Ring Stages in Western Cambodia , 2012, Antimicrobial Agents and Chemotherapy.

[56]  Y. Carlier,et al.  Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. , 2012, International journal of antimicrobial agents.

[57]  D. Kyle,et al.  4(1H)-Quinolones with Liver Stage Activity against Plasmodium berghei , 2012, Antimicrobial Agents and Chemotherapy.

[58]  J. Lelièvre,et al.  Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence “transmission blocking” assay , 2012, Malaria Journal.

[59]  R. Sinden,et al.  Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay. , 2012, International journal for parasitology.

[60]  Ian H. Gilbert,et al.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases , 2012, PLoS neglected tropical diseases.

[61]  M. Barrett,et al.  Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes , 2012, Proceedings of the National Academy of Sciences.

[62]  Mark C. Field,et al.  Epigenetic mechanisms, nuclear architecture and the control of gene expression in trypanosomes , 2012, Expert Reviews in Molecular Medicine.

[63]  S. Sundar,et al.  Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis , 2012, PLoS neglected tropical diseases.

[64]  N. Saravia,et al.  Novel Approach to In Vitro Drug Susceptibility Assessment of Clinical Strains of Leishmania spp , 2012, Journal of Clinical Microbiology.

[65]  M. Arkin,et al.  A high throughput drug screen for Entamoeba histolytica identifies a new lead and target , 2012, Nature Medicine.

[66]  K. Sashidhara,et al.  In vitro and in vivo antifilarial activity evaluation of 3,6-epoxy [1,5]dioxocines: a new class of antifilarial agents. , 2012, Bioorganic & medicinal chemistry letters.

[67]  G. Rádis-Baptista,et al.  Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms , 2012, Parasitology Research.

[68]  G. Rádis-Baptista,et al.  Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms , 2012, Parasitology Research.

[69]  Jiri Gut,et al.  WormAssay: A Novel Computer Application for Whole-Plate Motion-based Screening of Macroscopic Parasites , 2012, PLoS neglected tropical diseases.

[70]  V. Avery,et al.  Development and Optimization of a Novel 384-Well Anti-Malarial Imaging Assay Validated for High-Throughput Screening , 2012, The American journal of tropical medicine and hygiene.

[71]  Yingyao Zhou,et al.  Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery , 2011, Science.

[72]  Amanda L. Garner,et al.  Targeting the Wolbachia Cell Division Protein FtsZ as a New Approach for Antifilarial Therapy , 2011, PLoS neglected tropical diseases.

[73]  S. Maitra,et al.  Albendazole induces apoptosis in adults and microfilariae of Setaria cervi. , 2011, Experimental parasitology.

[74]  P. S. Murthy,et al.  Plant products in the treatment and control of filariasis and other helminth infections and assay systems for antifilarial/anthelmintic activity. , 2011, Planta medica.

[75]  A. Thomas,et al.  Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery , 2011, PloS one.

[76]  J. Gut,et al.  An image-based assay for high throughput screening of Giardia lamblia. , 2011, Journal of microbiological methods.

[77]  J. Keiser,et al.  Isothermal Microcalorimetry To Study Drugs against Schistosoma mansoni , 2011, Journal of Clinical Microbiology.

[78]  Catherine Z. Chen,et al.  High-Throughput Giardia lamblia Viability Assay Using Bioluminescent ATP Content Measurements , 2010, Antimicrobial Agents and Chemotherapy.

[79]  Alex Loukas,et al.  A Novel High Throughput Assay for Anthelmintic Drug Screening and Resistance Diagnosis by Real-Time Monitoring of Parasite Motility , 2010, PLoS neglected tropical diseases.

[80]  S. Mishra,et al.  Antifilarial activity in vitro and in vivo of some flavonoids tested against Brugia malayi. , 2010, Acta tropica.

[81]  Achim Hoerauf,et al.  Lymphatic filariasis and onchocerciasis , 2010, The Lancet.

[82]  Richa Sharma,et al.  Effect of Certain Antibiotics Against Filarial Parasite Brugia malayi In Vitro: Possible Role of Oxidative Stress , 2010, Indian Journal of Clinical Biochemistry.

[83]  Q. Bickle,et al.  Comparison of Microscopy and Alamar Blue Reduction in a Larval Based Assay for Schistosome Drug Screening , 2010, PLoS neglected tropical diseases.

[84]  K. Hoffmann,et al.  Development and Validation of a Quantitative, High-Throughput, Fluorescent-Based Bioassay to Detect Schistosoma Viability , 2010, PLoS neglected tropical diseases.

[85]  A. Souza,et al.  In vitro activities of plant extracts on human Loa loa isolates and cytotoxicity for eukaryotic cells , 2010, Parasitology Research.

[86]  F. Chappuis,et al.  NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness , 2010, PLoS neglected tropical diseases.

[87]  H. Vial,et al.  Reliability of Antimalarial Sensitivity Tests Depends on Drug Mechanisms of Action , 2010, Journal of Clinical Microbiology.

[88]  S. Croft,et al.  In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. , 2010, The Journal of antimicrobial chemotherapy.

[89]  S. Chevalley,et al.  Flow cytometry for the evaluation of anti-plasmodial activity of drugs on Plasmodium falciparum gametocytes , 2010, Malaria Journal.

[90]  Kami Kim,et al.  Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites. , 2009, The Journal of infectious diseases.

[91]  Conor R. Caffrey,et al.  Drug Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library of Known Drugs by Medium-Throughput Phenotypic Screening , 2009, PLoS neglected tropical diseases.

[92]  C. Carneiro,et al.  Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes. , 2008, The Journal of antimicrobial chemotherapy.

[93]  L. Bixby,et al.  Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease , 2008, Nature Medicine.

[94]  Solomon Nwaka,et al.  Schistosomes: challenges in compound screening , 2007, Expert opinion on drug discovery.

[95]  R. Mortara,et al.  Distribution of Trypanosoma cruzi stage-specific epitopes in cardiac muscle of Calomys callosus, BALB/c mice, and cultured cells infected with different infective forms. , 2007, Acta tropica.

[96]  L. Fox Ivermectin: uses and impact 20 years on , 2006, Current opinion in infectious diseases.

[97]  K. Balaraman,et al.  In vitro screening of medicinal plant extracts for macrofilaricidal activity , 2006, Parasitology Research.

[98]  M. Ouellette,et al.  Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. , 2006, The Journal of infectious diseases.

[99]  J. Sattabongkot,et al.  Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. , 2006, The American journal of tropical medicine and hygiene.

[100]  Mark J. Taylor,et al.  Onchocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro , 2006, Filaria journal.

[101]  Shailendra Singh,et al.  Synthesis, spectral studies and in vitro assessment for antiamoebic activity of new cyclooctadiene ruthenium(II) complexes with 5-nitrothiophene-2-carboxaldehyde thiosemicarbazones. , 2005, Bioorganic & medicinal chemistry letters.

[102]  T. Ezaki,et al.  Differential effects of diethylcarbamazine, tetracycline and the combination on Brugia pahangi adult females in vitro. , 2005, Parasitology international.

[103]  S. J. Upton,et al.  Application of Quantitative Real-Time Reverse Transcription-PCR in Assessing Drug Efficacy against the Intracellular Pathogen Cryptosporidium parvum In Vitro , 2005, Antimicrobial Agents and Chemotherapy.

[104]  S. Hoffman,et al.  Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  V. Srivastava,et al.  Acanthocheilonema viteae: octopamine and its physiological role. , 2004, Experimental parasitology.

[106]  A. Talman,et al.  Gametocytogenesis : the puberty of Plasmodium falciparum , 2004, Malaria Journal.

[107]  M. Doenhoff,et al.  Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. , 2004, International journal for parasitology.

[108]  P. Wilairat,et al.  Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening , 2004, Antimicrobial Agents and Chemotherapy.

[109]  P. Roepe,et al.  Novel, Rapid, and Inexpensive Cell-Based Quantification of Antimalarial Drug Efficacy , 2004, Antimicrobial Agents and Chemotherapy.

[110]  M. Rossi,et al.  Interferon-gamma-induced nitric oxide causes intrinsic intestinal denervation in Trypanosoma cruzi-infected mice. , 2004, The American journal of pathology.

[111]  P. Coley,et al.  A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. , 2004, The American journal of tropical medicine and hygiene.

[112]  P. Upcroft,et al.  Efficacy of antigiardial drugs , 2003, Expert opinion on drug safety.

[113]  E. Ramirez,et al.  Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. , 2003, The American journal of tropical medicine and hygiene.

[114]  C. Vnencak-Jones,et al.  Detection of Trypanosoma cruzi DNA within murine cardiac tissue sections by in situ polymerase chain reaction. , 2003, Memorias do Instituto Oswaldo Cruz.

[115]  B. Amadi,et al.  Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial , 2002, The Lancet.

[116]  M. Grijalva,et al.  AMPLIFICATION OF TRYPANOSOMA CRUZI–SPECIFIC DNA SEQUENCES IN FORMALIN-FIXED RACCOON TISSUES USING POLYMERASE CHAIN REACTION , 2002, The Journal of parasitology.

[117]  M. Arrowood In Vitro Cultivation of Cryptosporidium Species , 2002, Clinical Microbiology Reviews.

[118]  C. Wongsrichanalai,et al.  Histidine-Rich Protein II: a Novel Approach to Malaria Drug Sensitivity Testing , 2002, Antimicrobial Agents and Chemotherapy.

[119]  R. Rao,et al.  Brugia malayi: effects of antibacterial agents on larval viability and development in vitro. , 2002, Experimental parasitology.

[120]  A. Omar,et al.  In vitro antifilarial effects of three plant species against adult worms of subperiodic Brugia malayi. , 2001, Journal of Ethnopharmacology.

[121]  S. Tzipori,et al.  THE UTILIZATION OF SODIUM TAUROCHOLATE IN EXCYSTATION OF CRYPTOSPORIDIUM PARVUM AND INFECTION OF TISSUE CULTURE , 2001, The Journal of parasitology.

[122]  S. Gallati,et al.  Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. , 2001, Molecular and biochemical parasitology.

[123]  P. Upcroft,et al.  Drug Susceptibility Testing of Anaerobic Protozoa , 2001, Antimicrobial Agents and Chemotherapy.

[124]  W. Wernsdorfer,et al.  Effects of Miltefosine and Other Alkylphosphocholines on Human Intestinal ParasiteEntamoeba histolytica , 2001, Antimicrobial Agents and Chemotherapy.

[125]  C. Blanc,et al.  A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. , 2001, The American journal of tropical medicine and hygiene.

[126]  R. Nuñez,et al.  Flow cytometry analysis of the effect of allopurinol and the dinitroaniline compound (Chloralin) on the viability and proliferation of Leishmania infantum promastigotes , 2001, BMC pharmacology.

[127]  P. Upcroft,et al.  Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa , 2001, Clinical Microbiology Reviews.

[128]  J. Gama-Rodrigues,et al.  Life cycle of Trypanosoma cruzi (Y strain) in mice. , 1999, Revista do Hospital das Clinicas.

[129]  E. Tannich,et al.  Metronidazole Resistance in the Protozoan Parasite Entamoeba histolytica Is Associated with Increased Expression of Iron-containing Superoxide Dismutase and Peroxiredoxin and Decreased Expression of Ferredoxin 1 and Flavin Reductase* , 1999, The Journal of Biological Chemistry.

[130]  J. Gut,et al.  Cryptosporidium parvum: synchronized excystation in vitro and evaluation of sporozoite infectivity with a new lectin-based assay. , 1999, The Journal of eukaryotic microbiology.

[131]  S. Sundar,et al.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. , 1999, The Journal of infectious diseases.

[132]  R. Tarleton,et al.  Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. , 1999, The Journal of infectious diseases.

[133]  R. Kaminsky,et al.  A nucleoside transporter from Trypanosoma brucei involved in drug resistance. , 1999, Science.

[134]  D. Legros,et al.  Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[135]  R. Weber,et al.  Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: results of a 3-year longitudinal study. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[136]  R. Kissmehl,et al.  Transformation of Paramecium tetraurelia by Electroporation or Particle Bombardment , 1999, The Journal of eukaryotic microbiology.

[137]  J. Padierna,et al.  A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[138]  Joanne E. Harvey,et al.  A novel and simple colorimetric method for screening Giardia intestinalis and anti-giardial activity in vitro , 1998, Parasitology.

[139]  R. Kaminsky,et al.  Identification of three ABC transporter genes in Trypanosomabrucei spp. , 1997, Parasitology Research.

[140]  C. Vnencak-Jones,et al.  Detection of Trypanosoma cruzi with the polymerase chain reaction and in situ hybridization in infected murine cardiac tissue. , 1997, The American journal of tropical medicine and hygiene.

[141]  T. Davis,et al.  In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. , 1996, International journal for parasitology.

[142]  M. Russo,et al.  The influence of T cell subsets on Trypanosoma cruzi multiplication in different organs. , 1996, Immunology letters.

[143]  S. J. Upton,et al.  Effects of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells , 1995, Journal of clinical microbiology.

[144]  M Tilley,et al.  A simple and reliable method of producing in vitro infections of Cryptosporidium parvum (Apicomplexa). , 1994, FEMS microbiology letters.

[145]  W. Milhous,et al.  Causal prophylactic and radical curative activity of WR182393 (a guanylhydrazone) against Plasmodium cynomolgi in Macaca mulatta. , 1993, The American journal of tropical medicine and hygiene.

[146]  A. Oliveira,et al.  Follow-up of patent and subpatent parasitemias and development of muscular lesions in mice inoculated with very small numbers of Trypanosoma cruzi. , 1992, Experimental parasitology.

[147]  H. Vial,et al.  Use of radioactive ethanolamine incorporation into phospholipids to assess in vitro antimalarial activity by the semiautomated microdilution technique , 1992, Antimicrobial Agents and Chemotherapy.

[148]  T. Flanigan,et al.  In vitro screening of therapeutic agents against Cryptosporidium: hyperimmune cow colostrum is highly inhibitory. , 1991, The Journal of protozoology.

[149]  J. D. Smyth,et al.  In Vitro Cultivation of Parasitic Helminths , 1990 .

[150]  J. Louis,et al.  Trypanosoma cruzi: quantification in tissues of experimentally infected mice by limiting dilution analysis. , 1990, Experimental parasitology.

[151]  J. Comley,et al.  The further application of MTT-formazan colorimetry to studies on filarial worm viability. , 1989, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[152]  J. Comley,et al.  Colorimetric quantitation of filarial viability. , 1989, International journal for parasitology.

[153]  F. Chandler,et al.  Immunofluorescence as an adjunct to the histopathologic diagnosis of Chagas' disease , 1988, Journal of clinical microbiology.

[154]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[155]  J H Meuwissen,et al.  Synchronization of Plasmodium falciparum gametocytes using an automated suspension culture system , 1986, Parasitology.

[156]  R. Isturiz,et al.  Chagas Disease , 2021, Neglected Tropical Diseases.

[157]  T. Seemayer,et al.  ACQUIRED IMMUNODEFICIENCY SYNDROME WITH SEVERE GASTROINTESTINAL MANIFESTATIONS IN HAITI , 1983, The Lancet.

[158]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.

[159]  L. Sax,et al.  DRUG SENSITIVITY OF PLASMODIUM FALCIPARUM An In-vitro Microtechnique , 1978, The Lancet.

[160]  W. Trager,et al.  Human malaria parasites in continuous culture. , 1976, Science.

[161]  THE WORLD HEALTH ORGANIZATION , 1954 .

[162]  Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015 .

[163]  R. Tarleton,et al.  New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. , 2014, The Journal of infectious diseases.

[164]  E. Reisinger,et al.  Schistosoma mansoni: schistosomicidal effect of mefloquine and primaquine in vitro. , 2011, Experimental parasitology.

[165]  Organización Mundial de la Salud Guidelines for the treatment of malaria , 2010 .

[166]  R. Rao,et al.  Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms and microfilariae of filarial nematodes. , 2009, Experimental parasitology.

[167]  E. Oldfield,et al.  Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. , 2004, Journal of medicinal chemistry.

[168]  K. Mehta,et al.  Identification and localization of glutathione S-transferase as a potential target enzyme in Brugia species , 2000, Parasitology Research.

[169]  M. Dumas,et al.  Treatment of human African trypanosomiasis. , 2000, Bulletin of the World Health Organization.

[170]  H. Eisen,et al.  Persistence of Trypanosoma cruzi antigens in the inflammatory lesions of chronically infected mice. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[171]  R. Sinden Sexual development of malarial parasites. , 1983, Advances in parasitology.

[172]  F. Köberle The causation and importance of nervous lesions in American trypanosomiasis. , 1970, Bulletin of the World Health Organization.